Research Analysts Set Expectations for ATOS FY2026 Earnings

Atossa Therapeutics, Inc. (NASDAQ:ATOS) – HC Wainwright cut their FY2026 earnings per share (EPS) estimates for Atossa Therapeutics in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.32) per share for the year, down from their previous estimate of ($0.21). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Atossa Therapeutics’ current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Atossa Therapeutics’ FY2027 earnings at ($0.27) EPS and FY2028 earnings at ($0.21) EPS.

A number of other analysts have also commented on the company. StockNews.com lowered Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 8th. Ascendiant Capital Markets lifted their price target on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a research report on Wednesday, September 11th.

Atossa Therapeutics Stock Down 6.6 %

Shares of NASDAQ ATOS opened at $1.28 on Friday. Atossa Therapeutics has a 12-month low of $0.65 and a 12-month high of $2.31. The firm has a market cap of $160.97 million, a PE ratio of -5.82 and a beta of 1.23. The company’s fifty day simple moving average is $1.44 and its 200 day simple moving average is $1.38.

Hedge Funds Weigh In On Atossa Therapeutics

Several hedge funds have recently modified their holdings of ATOS. XTX Topco Ltd purchased a new position in Atossa Therapeutics in the second quarter worth $29,000. Intech Investment Management LLC bought a new position in Atossa Therapeutics during the third quarter valued at $29,000. SG Americas Securities LLC increased its position in Atossa Therapeutics by 254.3% in the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after buying an additional 30,037 shares during the last quarter. Cetera Advisors LLC bought a new stake in shares of Atossa Therapeutics in the first quarter valued at $72,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Atossa Therapeutics during the 3rd quarter worth $75,000. Institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.